Cover Image
市場調查報告書

全球的搭配診斷市場

Companion Diagnostics

出版商 Global Industry Analysts, Inc. 商品編碼 222510
出版日期 內容資訊 英文 278 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球的搭配診斷市場 Companion Diagnostics
出版日期: 2016年05月01日 內容資訊: 英文 278 Pages
簡介

本報告,調查全球的搭配診斷市場,彙整業界動向與產品概要、主要參與企業的檔案資料、全球主要各國市場的動向,由下列摘要形式闡述。

第1章 簡介、方法論、產品的定義

第2章 業界概要

  • 搭配診斷:開拓個人化醫療的道路
  • 在搭配診斷上扮演一部份角色的國際法令機關
  • 現在以及將來分析

第3章 市場動向

  • 做為醫藥品業界的萬能方式的課題
  • 開拓個人化醫療的道路
  • 廣泛範圍與應用
  • 獲得市佔率的診斷藥物製造商
  • 搭配診斷的成長加速因子
  • 醫藥品與診斷藥物的交易增加
  • 個人化醫療的促進因子
  • 市場參與
  • 生物標記於搭配診斷上的角色
  • 全球主要市場上的法律規範情境
  • 各式各樣利害關係人所期待的事

第4章 產品概要

  • 個人化醫療的診斷藥物
  • 搭配診斷:高價
  • 用於搭配診斷的技術
  • PCR技術多使用於搭配診斷上
  • 臨床實驗上的搭配診斷
  • 主要治療領域上的搭配診斷

第5章 近年的業界活動

第6章 主要企業

  • Abbott Laboratories
  • Abbott Molecular
  • bioMerieux
  • Clarient Inc.
  • LabCorp
  • Merck & Co. Inc.
  • Myriad Genetics, Inc.
  • Power3 Medical Products, Inc.
  • QIAGEN NV
  • Roche Diagnostics Corp.
  • Theranostics Health

第7章 全球市場展望

第8章 美國

第9章 日本

第10章 歐洲

  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他國家

第11章 其他地區

企業檔案資料:101家

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6736

This report analyzes the worldwide markets for Companion Diagnostics in US$ Million. The Global market is further analyzed by the following Therapeutic Areas: Oncology, Neurology, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 80 companies including many key and niche players such as -

Abbott Molecular Inc.
Beckman Coulter, Inc.
bioMerieux SA
Dako A/S
Foundation Medicine, Inc.

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

  • Companion Diagnostics: Leading the Way to Personalized Medicine
    • Table 1: Number of Companion Diagnostic Tests by Disease Area: 2004-2008 (includes corresponding Graph/Chart)
  • Roche's Got an Edge Over its Counterparts
    • Select Popular Drugs with Companion Diagnostics
  • International Regulatory Agencies Doing their Part for Companion Diagnostics
  • Current and Future Analysis

3. MARKET TRENDS

  • Companion Diagnostics: Challenging the One-Size-Fits- All Approach of the Pharmaceutical Industry
  • Companion Diagnostics Make Way for Personalized Medicine
  • Companion Diagnostics: Broader Scope and Applications Aplenty
  • Diagnostics Companies to Receive their Due Share
  • Diagnostics to Benefit at Large from Companion Diagnostics
  • Factors Fuelling the Growth of Companion Diagnostics
  • Companion Diagnostics to Play a Decisive Role in the Commercial Success of Drugs in Future
  • Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostics Capabilities
  • Market to Witness Increasing Pharmaceutical and Diagnostic Deals
    • Table 2: Companion Diagnostics: Number of Partnership Deals by Select Global Players (includes corresponding Graph/Chart)
  • Select Deals between Pharmaceutical and Diagnostics Companies (2007-2011)
  • Select Companion Diagnostics Alliances (2008): By Company and Corresponding Collaborator
  • Drive Towards Individualized Medicine to Remain a Major Market Driver
  • Enter Companion Diagnostics
  • Role of Biomarkers in Companion Diagnostics
  • Regulatory Scenario in Leading Global Markets
  • Differences between Companion Diagnostics and Laboratory Diagnostic Tests (LDTs)
  • Drugs with Companion Diagnostics: Labeling Approach based on Risk Involved
  • Drugs Requiring Companion Diagnostics Tests as Mandated by the FDA
  • Drugs Requiring Companion Diagnostics Tests as Mandated by the EMEA
  • What is Expected of the FDA Henceforth?
  • Companion Diagnostics: What Various Stakeholders Expect?
  • Pharmaceutical Company (Drug Manufacturer)
  • Diagnostic Company (Companion Diagnostic Manufacturer)
  • Patients
  • Physician/Healthcare Professional
  • Payer
    • Revised Payer Strategy: Need of the Hour
  • Competitive Scenario

4. PRODUCT OVERVIEW

  • Diagnostics in Personalized Medicine
  • Genetic Tests
  • Companion Diagnostics
  • Companion Diagnostics: What Makes them Work
  • Techniques Used in Companion Diagnostics
  • PCR Technology Proves to be of Significant Use in Companion Diagnostics
  • QuantaLife ddPCR(tm) System: A Breakthrough Innovation in the Field of Companion Diagnostics
  • Biomarkers as Companion Diagnostics
  • Herceptin and Vilazodone -References for Success of Biomarker Based Approach
  • Applications of Companion Diagnostics at a Glance
  • Role of Companion Diagnostics in the Drug Development Process
  • Companion Diagnostics in Clinical Trials
  • Companion Diagnostics in Select Therapeutic Areas
  • Companion Diagnostics in Oncology
  • Select Companion Diagnostics in Cancer
    • Oncotype DX(r)
      • Quantitative Recurrence Score
      • Early Development and Clinical Trials
      • Oncotype DX: Early Development and Outcomes by Trial Studies
      • Ongoing Trial
      • Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision
      • Eligibility
      • The Test Procedure
      • Result Interpretation
      • Reimbursement for Oncotype DX
    • Molecular Grade Index (MGISM) (bioTheranostics)
    • Breast Cancer IndexSM (bioTheranostics)
    • KRAS Testing
    • The Test Procedure
    • HER2 Testing for Herceptin Treatment in Breast Cancer
      • Assays Used for HER2 Testing
    • MammaPrint
      • Validation
      • Ongoing Clinical Trials
      • I-SPY Trials
    • HER-2/neu Blood Test
    • Mammostrat
    • CupPrint Test to Aid Cancer Treatment
    • The EGFRx(tm) Assay to Aid Cancer Treatment
    • c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation)
    • TheraGuide 5-FU(tm)
      • Select Drugs and Companion Diagnostic Tests by Companies and FDA Status (Oncology): 2009
  • Companion Diagnostics in Inflammatory
    • PROMETHEUS(r) IBD Serology 7 for Irritable Bowel Disease
  • Companion Diagnostics in Infectious Diseases
    • Trofile(tm) Assay (Monogram Biosciences) to Aid in HIV Treatment
      • Select Drug and Companion Diagnostic Tests by Companies and FDA Status (Infectious Diseases): 2009
  • Companion Diagnostics In Drug Metabolism
    • AmpliChip(r) CYP450 Test
    • HILOmet PhyzioType(tm) System (Genomas)
    • Warfarin Sensitivity Test
      • Select Drugs and Companion Diagnostic Tests by Companies and FDA Status (Other Diseases)
      • Select Drugs with Companion Diagnostics Labeling
  • An Account of Companion Diagnostics Companies in the CNS Arena

5. RECENT INDUSTRY ACTIVITY

  • LabCorp to Take Over Clearstone Central Laboratories
  • Nanosphere Seeks FDA Approval for Plavix Metabolism Assay and Troponin I Assay
  • Thermo Fisher to Take Over Phadia
  • Sanofi-Aventis Takes Over Genzyme Corp.
  • Ariad Partners with MolecularMD for Companion Diagnostics Development
  • CompanDX and CRL Join Forces to Develop Companion Diagnostics and Biomarkers
  • CST Grants Ventana Non-Exclusive Global License Related to Tissue-based IVD Testing
  • Luminex Partners with Partners HealthCare for Development of New Molecular Assays
  • Unilabs and Biogen to Offer Novel Companion Diagnostics Assay
  • Proteome Sciences and Buck Institute to Develop Biomarker Assay to Aid Breast Cancer Treatment
  • Myriad Genetics Takes Over Rules-Based Medicine
  • Roche to Develop Companion Diagnostics for Merck's Oncology Pipeline Drugs
  • Biodesix Obtains NY State Certification Under the Clinical Laboratory Evaluation Program
  • ExonHit Therapeutics is Now Exonhit
  • bioTheranostics Presents Outcome of Clinical Studies on Breast Cancer Index(r) and CancerTYPE ID(r) Tests
  • Pharmigene Collaborates with 50 Taiwanese Hospitals, Provides Novel Companion Diagnostics Test
  • Morphotek and Biocare Medical Join Forces to Develop Diagnostic Kits for Detecting FRA+ Cancer Patients
  • Seegene and Samsung Combine Forces for Molecular Diagnostics Test Development in Cancer
  • Clovis Oncology and Roche to Develop Companion Diagnostics for NSCLC
  • MDxHealth Demonstrates Successful Clinical Utility of Predict MDx
  • Pharmigene and University of Washington to Implement a Licensing Deal
  • Phadia Launches Novel Companion Diagnostic Tests
  • Caliper forms Alliance with Seegene to Expand Diagnostic Tests Portfolio
  • Ventana Obtains FDA Approval for INFORM HER2 Assay for Breast Cancer
  • Celgene to Use Foundation Medicine's Companion Diagnostic Test for Ongoing Drug Trials in Oncology
  • Roche to Co-develop Cancer Biomarkers with Evotec
  • Quest Diagnostics Takes Over Celera Corp.
  • Forest Laboratories Takes Over Clinical Data, Inc.
  • Source MDx Announces Assets Liquidation
  • bioMerieux and Ipsen Team Up
  • Invivoscribe Inks Agreement with Novartis
  • Novartis to Acquire Genoptix
  • TcLand Receives Funding for Rheumatoid Arthritis
  • WILEX to Take Over Siemens' Oncogene Science Business
  • Aeterna Zentaris to Partner with Almac for Cancer Therapeutic and Companion Diagnostic Development
  • Bayer Partners with Prometheus for Companion Diagnostics Development in Cancer Treatment
  • Genzyme Extends DxS' License for EGFR Diagnostics to Canada and the US
  • Almac Joins Forces with Merck and MRC Companion Diagnostics Development for Erbitux
  • bioMerieux Partners with GSK to Co-develop New Companion Diagnostics Test to aid Cancer Treatment
  • Power3 Medical Reports Novel Clinical Findings
  • Genetic Technologies Purchases Assets of Perlegen Sciences
  • Caliper Life Sciences Acquires Cambridge Research & Instrumentation
  • Flagship Partners with HistologiX to Provide Companion Diagnostics in Europe
  • MDxHealth Establishes New Business Division, MDxHealth PharmacoDx
  • Compendia and AltheaDx Enter into Partnership Deal to Consolidate Bioinformatics Services
  • Roche Bags License from Genzyme, Plans to Develop Tarceva with OSI
  • Dako Denmark Forms Alliance with Quintiles
  • Sirius Genomics and Golden Helix to Jointly Develop Companion Diagnostics
  • Sirius Genomics to Receive Funding from NRC-IRAP
  • Ventana Inks Agreement with Transgene to Develop Novel Assay
  • Array BioPharma Partners with Signal Genetics to Develop Multiple Myeloma Program
  • Aterovax Collaborates with Biomnis
  • QIAGEN Inks Distribution Agreement with Roche Molecular Systems
  • Clovis Enters Agreement with Ventana for Developing Companion Diagnostic Test US
  • Roche Molecular Systems Collaborates with Merck Sharp & Dohme
  • Debiopharm Group(tm) Inks Companion Diagnostic Development Agreement with Biocartis
  • GSK and Abbott to Collaborate for Diagnostic Test Development
  • QIAGEN Acquires PI3K Biomarker Exclusive Licence from Johns Hopkins University
  • QIAGEN Inks Agreement with Pfizer for Developing Novel Companion Diagnostic Test
  • AstraZeneca Inks Agreement with Dako for Development of Oncology Companion Diagnostics
  • Horizon Discovery Establishes Horizon Dx
  • MDxHealth to Ink Partnership Agreement with Pfizer, Cancer Research Technology and Newcastle University
  • OncoMethylome Enters Into Agreement with Glaxo SmithKline Biologicals
  • AVEO Pharmaceuticals Obtains Patents for Companion Diagnostic Tests
  • Dako Denmark Introduces HER2 CISH pharmDxTM Kit QIAGEN Introduces Tests for Cancer Companion Diagnostics
  • 20/20 GeneSystems Introduces L-IHC Technology
  • Lab21 Introduces Companion Diagnostic for HIV
  • Saladax Receives $8 million for MyCare(tm) Expansion
  • Avacta Group Enters into Partnership with Takeda
  • TcLand Signs Agreement with Inserm
  • Sequenom Obtains License to Develop and Market Predictive Diagnostic Test for Genetic Predisposition of AMD
  • Kalgene Inks Agreement with Affomix for Development of Therapeutics and Companion Diagnostics
  • DxS Enters into Collaboration Agreement with ImClone Systems and Bristol-Myers Squibb
  • Psynova Neurotech Teams Up with Roche for Schizophrenia Treatment Development
  • QIAGEN Takes Over DxS
  • Eli Lilly Inks Agreement with Almac
  • Pfizer and Abbott Collaborate for Molecular Diagnostic Test Development
  • Dako Denmark Inks Agreement with Genentech
  • Novartis International Seeks Approval for Prexige
  • LabCorp Acquires Monogram Biosciences
  • AstraZeneca Collaborates with DxS
  • Exosome Diagnostics to Collaborate with DxS
  • Boehringer Ingelheim Inks Agreement with DxS
  • Novartis Extends Collaboration with Gen-Probe
  • Dako and OSI Pharmaceuticals Enter into Collaboration
  • Horizon and DxS Collaborates for New Companion Diagnostic Tests
  • Asuragen and Biogen Idec Ink Agreement for Developing Novel Companion Diagnostic
  • DxS' TheraScreen(r) K-RAS Companion Diagnostic Obtains Canadian Approval Canada; 13 Jul 2009
  • Roche Declares the Results of a Phase I Study on PLX4032
  • Gen-Probe to Take Over Tepnel
  • IPSOGEN Introduces MapQuant Dx(tm) HER2 test in Europe
  • LabCorp(r) and Vanda to Co-Develop Several Diagnostic Tests for Pharmacogenetic Markers
  • Theranostics Secures Exclusive License from NIH
  • Reckitt Benckiser Takes Over Adams Respiratory Therapeutics
  • National Jewish Health Signs Agreement with Laboratory Corporation of America Holdings
  • DxS Collaborates with Amgen to Provide A K-RAS Companion Diagnostic for Vectibix(r)
  • Dako Collaboration with Genentech on a New Companion Diagnostic
  • Celera Partners with Abbott for Identifying Pharmacogenomic Markers
  • Tethys Bioscience Acquires Lipomics Technologies
  • The Immune Tolerance Institute Collaborates with Beckman Coulter
  • Amgen and Lab21 Collaborate to Target Predictive Genetic Test For Bowel Cancer
  • LabCorp Acquires Tandem Labs
  • Roche to Acquire Ventana
  • Siemens Inks Non-Exclusive Deal with Laboratory Corporation of America(r) Holdings
  • GE and Eli Lilly Enter a Research Agreement
  • Agilent and Lipomics to Co-Develop Assays for Metabolic Diseases
  • Celerus Diagnostics Accomplishes Automated Rapid ISH(tm) (US)
  • Debiopharm GroupTM Inks Agreement with Biocartis
  • F. Hoffmann-La Roche Inks Agreement with Itamar Medical
  • Linkage Biosciences Enhance LinkSeqTM HLA Product Line
  • Asuragen and Merck Enter Collaboration to Develop Novel Pharmacogenomic Tests
  • bioMerieux and Ipsen Team Up
  • LabCorp Partners with ARCA Discovery for Commercial Development of Companion Diagnostic Test for Heart Failure Drug
  • EPIDAUROS and Osmetech(r) Enter into Agreement

6. FOCUS ON SELECT PLAYERS

  • Abbott Laboratories (US)
  • Abbott Molecular (US)
  • bioMerieux (France)
  • Clarient Inc. (US)
  • LabCorp (US)
  • Merck & Co. Inc. (US)
  • Myriad Genetics, Inc. (US)
  • Power3 Medical Products, Inc. (US)
  • QIAGEN NV (The Netherlands)
  • Qiagen: Companion Diagnostics Tests by Therapeutic Applications and Regulatory Status
  • Companion Diagnostics: Pipeline Biomarkers by Type of Cancer (April 2010)
  • Roche Diagnostics Corp. (US)
    • Table 3: Roche Diagnostics: Companion Diagnostics in Various Stages of Development (2009)
  • Virology and Oncology: Therapeutic Areas in Focus in Companion Diagnostics
  • Theranostics Health (USA)

7. GLOBAL MARKET PERSPECTIVE

    • Table 4: World Recent Past Current & Future Analysis for Companion Diagnostics Market by Geographic Region - US, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)
    • Table 5: World 10-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

8. THE UNITED STATES

  • A. Market Analysis
    • A Prelude
    • Companion Diagnostics: A Novel Paradigm in Prescribing Drugs
    • Need for Convergence of Pharmaceutical and Diagnostics Companies
    • Developing a Companion Diagnostic for Targeted Therapies Drives Companies into a Tight Spot
    • Companion Diagnostics from Early Stages of Drug Development
    • Development of Companion Diagnostics in Oncology: A Historic Review
    • Earlier Fruitful Attempts at Companion Diagnostics Development
    • Increasing Number of Deals, Collaborations, and Partnerships
    • Joint Development of Drugs and their Companion Diagnostics: An Upcoming Trend
    • Number of Companion Diagnostics being Developed Keeps Soaring
      • Majority of Companion Diagnostics have been Developed Independent of the Drug
    • Potential in Curbing Healthcare Costs to Drive Companion Diagnostics Adoption in the US
      • Companion Diagnostics Labeling: Tests Mandated by FDA
      • Companion Diagnostics Labeling: Tests Recommended by FDA
      • Companion Diagnostics 'For Informational Use' Tests
    • Strategic Corporate Developments
    • Key Players
      • Abbott Laboratories (US)
      • Abbott Molecular (US)
      • Clarient Inc. (US)
      • LabCorp (US)
      • Merck & Co. Inc. (US)
      • Myriad Genetics, Inc. (US)
      • Power3 Medical Products, Inc. (US)
      • Roche Diagnostics Corp. (US)
    • Table 6: Roche Diagnostics: Companion Diagnostics in Various Stages of Development (2009)
      • Virology and Oncology: Therapeutic Areas in Focus in Companion Diagnostics
      • Theranostics Health (USA)
  • B. Market Analytics
    • Table 7: The US Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

9. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 8: Japanese Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

10. EUROPE

  • A. Market Analysis
    • Table 9: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)
    • Table 10: Drug Development Pipeline with Biomarker (2009): By Therapeutic Area (Europe) (includes corresponding Graph/Chart)
    • Table 11: Pipeline Projects for Select Therapeutic Areas: Percentage Share of Pipeline Projects With or Without Biomarkers (2009) (includes corresponding Graph/Chart)
    • Regulatory Scenario in Europe
      • Companion Diagnostics: Select European Players with Strong Biomarker Pipeline
    • Strategic Corporate development
    • QIAGEN NV (The Netherlands): A Key Player
  • B. Market Analytics
    • Table 12: European Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)
    • Table 13: European 10-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)

10a. FRANCE

  • A. Market Analysis
    • Strategic Corporate Development
    • bioMerieux (France): A Key Player
  • B. Market Analytics
    • Table 14: French Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

10b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 15: German Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

10c. ITALY

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 16: Italian Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

10d. THE UNITED KINGDOM

  • A. Market Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 17: The UK Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

10e. REST OF EUROPE

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 18: Rest of European Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

11. REST OF WORLD

  • A. Market Analysis
    • Strategic Corporate development
  • B. Market Analytics
    • Table 19: Rest of the World Recent Past, Current & Future Analysis for Companion Diagnostics Market - Analyzed by Annual Revenue Figures in US$ Thousand for Years 2008 through 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top